Abstract
This work establishes the synergistic efficacy of combined FLT3 and LSD1 inhibition in FLT3-ITD AML by disrupting STAT5 and GFI1 binding at the MYC blood-specific superenhancer complex.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have